
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with expectations for growth to $130.4 million in 2026, indicating a strong trajectory in revenue generation. The favorable market access situation is anticipated to enhance coverage over the coming months, potentially contributing to an increase in revenue beyond the current forecasts. Additionally, the company's promising pipeline assets, including therapies for rare genetic diseases, are expected to provide incremental upside to the financial outlook as their clinical development progresses.
Bears say
Abeona Therapeutics faces significant risks that contribute to a negative outlook on its stock, notably the potential for slower-than-projected market uptake of its flagship product, pz-cel, in the United States. Additionally, the company's inability to effectively capitalize on pz-cel’s value outside of the U.S. and challenges with earlier-stage pipeline programs further exacerbate concerns about its growth potential. Furthermore, there exists a persistent risk of long-term dilution, which may adversely affect shareholder value and investor confidence.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares